Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News


SUDA AGM Presentation


Observations from the Chair 

  • The technology is sound
  • Solid barriers to entry as evidenced by our partners’ willingness to engage
  • Shareholder sentiment at an all time low
  • Investor communications must be improved & confidence restored
  • Company’s business model is not well understood
  • Some investor’s expectations are not aligned with the reality of the business
  • Many investors fail to recognise that raising capital is an intrinsic feature of life science companies
  • Long lead times are part of the business model notwithstanding the accelerated pathway of 505(b)(2) drug development takes time
  • Need to revitalise management

For more information, download the attached PDF.





  Download this document